{"doi":"10.3390/tomography9020041","title":"Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer","abstract":"Early response assessment is critical for personalizing cancer therapy. Emerging therapeutic regimens with encouraging results in the wild-type (WT) KRAS colorectal cancer (CRC) setting include inhibitors of epidermal growth factor receptor (EGFR) and glutaminolysis. Towards predicting clinical outcome, this preclinical study evaluated non-invasive positron emission tomography (PET) with (4S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) in treatment-sensitive and treatment-resistant WT KRAS CRC patient-derived xenografts (PDXs). Tumor-bearing mice were imaged with [18F]FSPG PET before and one week following the initiation of treatment with either EGFR-targeted monoclonal antibody (mAb) therapy, glutaminase inhibitor therapy, or the combination. Imaging was correlated with tumor volume and histology. In PDX that responded to therapy, [18F]FSPG PET was significantly decreased from baseline at 1-week post-therapy, prior to changes in tumor volume. In contrast, [18F]FSPG PET was not decreased in non-responding PDX. These data suggest that [18F]FSPG PET may serve as an early metric of response to EGFR and glutaminase inhibition in the WT KRAS CRC setting.","journal":"Tomography","year":2023,"id":340737,"datarank":0.8144972395615437,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.3986089312255765,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.3986089312255765,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":13,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9551,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT 03263429"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":998503,"name":"Jianbo Wang","orcid":"0000-0003-4879-974X","position":1,"is_corresponding":false},{"id":393493,"name":"Dimitra K. Georgiou","orcid":"0000-0001-8786-2495","position":2,"is_corresponding":false},{"id":409051,"name":"Xiaoxia Wen","orcid":"0000-0002-7181-5165","position":3,"is_corresponding":false},{"id":357354,"name":"Allison S. Cohen","orcid":null,"position":4,"is_corresponding":false},{"id":357355,"name":"Ling Geng","orcid":null,"position":5,"is_corresponding":false},{"id":479401,"name":"Mohammed Noor Tantawy","orcid":"0000-0001-5975-7540","position":6,"is_corresponding":false},{"id":614785,"name":"H. Charles Manning","orcid":"0009-0008-6938-4811","position":7,"is_corresponding":false},{"id":1075784,"name":"Seong-Woo Bae","orcid":"0000-0001-6530-3983","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T01:10:58.548803Z","pmid":"36961000","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}